Journals / Journal of Neurological Sciences (Turkish) / 2011 / Cilt: 28 - Sayı: 3

Cerrahi Çıkarım Yapılan Anaplastik Astrositomların ve Glioblastomların Sağkalım Analizi: Tek Merkezli Retrospektif Çalışma Sonuçları

The Outcome of Surgically Resected Anaplastic Astrocytoma and Glioblastoma: Results of Single Center Retrospective Study

Pages
347–354
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patients (n=164) who died in this period have been included inthis study.Results: Overall survival of the patients with anaplastic astrocytomas was 25.4 months; and8.3 months for glioblastomas; six months progression free survival was 42.5% for patientswith anaplastic astrocytomas; and 14.5% for those with glioblastomas.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Anaplastic astrocytomas and glioblastomas are the most common primary cerebralneoplasms in adults.
📊
Key Findings & Data:We report the outcome of surgicallyresectioned anaplastic astrocytomas and glioblastomas in our clinic.Methods: We retrospectively analyzed the records including age of diagnosis, preoperativeKarnofsky performance score, survival period, histological grade of the tumor; extend ofsurgical resection, and postoperative treatment status of all anaplastic astrocytomas andglioblastomas operated.
💡
Conclusion & Impact:The patients (n=164) who died in this period have been included inthis study.Results: Overall survival of the patients with anaplastic astrocytomas was 25.4 months; and8.3 months for glioblastomas; six months progression free survival was 42.5% for patientswith anaplastic astrocytomas; and 14.5% for those with glioblastomas.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Anaplastic astrocytomas and glioblastomas are the most common primary cerebralneoplasms in adults. Unfortunately, despite newly developed therapies and surgicaltechniques, the clinical course of anaplastic astrocytomas and glioblastomas is very rapid andalmost always they have miserable prognosis. We report the outcome of surgicallyresectioned anaplastic astrocytomas and glioblastomas in our clinic.Methods: We retrospectively analyzed the records including age of diagnosis, preoperativeKarnofsky performance score, survival period, histological grade of the tumor; extend ofsurgical resection, and postoperative treatment status of all anaplastic astrocytomas andglioblastomas operated. The patients (n=164) who died in this period have been included inthis study.Results: Overall survival of the patients with anaplastic astrocytomas was 25.4 months; and8.3 months for glioblastomas; six months progression free survival was 42.5% for patientswith anaplastic astrocytomas; and 14.5% for those with glioblastomas. Six months and 1 yearsurvival rates of gross total removal plus near total removal group were 76.8% and 45.8%respectively. Six months and 1 year survival rates of subtotal removal group was 55.6% and22.2% respectively.Conclusion: As expected, overall survival tends to be longer for patients with anaplasticastrocytomas. Overall survival and life expectation were longer for patients with six monthsprogression free survival. Preoperative high Karnofsky performance score and younger age atthe time of diagnosis were associated with good prognosis. Gross total removal plus near totalremoval group had higher survival rates compared with subtotal removal group and biopsygroups.

Özet

Amaç: Anaplastik astrositomlar ve glioblastomlar en sık görülen primer santral sinir sistemineoplazmıdır. Ne yazık ki, gelişen tedavi yöntemlerine ve cerrahi tekniklere rağmen butümörlerin klinik seyirleri çok hızlıdır ve prognozları hemen her zaman kötüdür. Buçalışmada, kliniğimizde cerrahi uygulanan anaplastik astrositomların ve glioblastomların sağkalım analizi yapılmıştır.Yöntem: Kliniğimizde Ocak 2005 ile Aralık 2009 tarihleri arasında opere edilen anaplastikastrositom ve glioblastom tanılı hastaların tanı anındaki yaşları, ameliyat öncesi Karnofskyperformans skorları, sağ kalım süreleri, tümörün histopatolojik evresi, cerrahi çıkarım oranıve ameliyat sonrası tedavi durumları geriye dönük olarak analiz edildi. Bu periyotta ölen 164hasta çalışmaya dahil edildi.Bulgular: Anaplastik astrositomların ortalama sağ kalım süresi 25.4 ay; glioblastomlarınortalama sağ kalım süresi ise 8.3 ay olarak bulundu. 6 aylık progresyonsuz sağ kalımanaplastik astrositomların %42.5'inde; glioblastomların %14.5'inde sağlanmıştır. Gross totalve totale yakın cerrahi çıkarım yapılan hastaların 6 aylık ve 1 yıllık sağ kalım oranlarısırasıyla, %76.8 ve %45.8 olarak bulunmuştur; subtotal çıkarım yapılan hastalarda ise buoranlar %55.6 ve %22.2 olarak bulunmuştur.Sonuç: Beklendiği üzere anaplastik astrositomların sağ kalım oranları daha uzundur. 6 ayprogresyonsuz sağ kalım sağlanan hastaların uzun süreli sağ kalım oranları ve yaşambeklentileri daha fazladır. Ameliyat öncesi yüksek Karnofsky performans skoru olan ve tanıanında daha genç yaşta olan hastaların prognozları daha iyidir. Gross total ve totale yakınçıkarım yapılan hastaların sağ kalım oranları subtotal çıkarım yapılan ve biopsi yapılangruplardan daha fazladır.

🔖

Cite This Article

GÜRER, B., ŞANLI, A. M., DOLGUN, H., ŞEKERCI, Z., YILMAZ, E. R., KERTMEN, H. (2022). Cerrahi Çıkarım Yapılan Anaplastik Astrositomların ve Glioblastomların Sağkalım Analizi: Tek Merkezli Retrospektif Çalışma Sonuçları. Journal of Neurological Sciences (Turkish), Cilt: 28 - Sayı: 3, 347–354. https://ajindex.com/articles/565317

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY. The outcomes of concomitant chemoradiotherapy f ollowed by adj uvant chemotherapy with temozolomide f or newly diagnosed high grade gliomas: the preliminary results of single center prospective study. J Korean Neurosurg Soc 2008; 44: 222-7 2. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al. Recursive partitioning analysis of prognostic f actors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-10 3. Farrell CJ, Plotkin SR. Genetic causes of brain tumors: neurof ibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin 2007; 25: 925-46 4. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin 2007; 25: 867-90 5. Galanis E, Buckner JC. Chemotherapy of brain tumors. Curr Opin Neurol 2000; 13: 619-25 6. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD; North American Brain Tumor Consortium. Progression- f ree survival: an important end point in evaluating therapy f or recurrent high-grade gliomas. Neuro Oncol 2008; 10: 162-70 7. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classif ication of tumors of the central nervous system. Acta Neuropathol 2007; 114: 97-109 8. Mahaley MS Jr, Mettlin C, Nataraj an N, Laws ER Jr, Peace BB. National survey of patterns of care f or brain-tumor patients. J Neurosurg 1989; 71: 826-36 9. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and f uture directions. J Clin Oncol 2007; 25: 4127-36 10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation f or Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adj uvant temozolomide f or glioblastoma. N Engl J Med 2005; 352: 987-96 11. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507